Laiboruichen completes A++ round of financing, Baheal Medical Group leads the investment
Recently, Zhongshan Laiboruichen Biopharmaceutical Co., Ltd. completed the signing and delivery with investors including Baheal Medical Group, Dongfang Chenxing, Shengnuo Biotech, and Chenghai Venture Capital, successfully raising funds in the A++ round. This round of financing was led by Baheal Medical Group, with follow-on investments from Dongfang Chenxing, Shengnuo Biotech, and Chenghai Venture Capital. Additionally, existing shareholder Zhuhai Yihao also continued to increase their investment. The funds raised will be primarily used to advance the pipeline projects RAB001d and RAB202, while also strengthening the company's technology platform and team building
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments